These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 31318041)

  • 81. Validation of the Itch Severity Item as a Measurement Tool for Pruritus in Patients with Psoriasis: Results from a Phase 3 Tofacitinib Program.
    Ständer S; Luger T; Cappelleri JC; Bushmakin AG; Mamolo C; Zielinski MA; Tallman AM; Yosipovitch G
    Acta Derm Venereol; 2018 Mar; 98(3):340-345. PubMed ID: 29182790
    [TBL] [Abstract][Full Text] [Related]  

  • 82. First Oral Drug for Moderate-To-Severe Ulcerative Colitis.
    Aschenbrenner DS
    Am J Nurs; 2018 Sep; 118(9):22-23. PubMed ID: 30138199
    [No Abstract]   [Full Text] [Related]  

  • 83. Tofacitinib in ulcerative colitis.
    Archer TP; Moran GW; Ghosh S
    Immunotherapy; 2016 May; 8(5):495-502. PubMed ID: 27140405
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Two birds that exclude each other: the Renbök phenomenon.
    Mirmirani P
    J Invest Dermatol; 2015 Apr; 135(4):1180. PubMed ID: 25431848
    [No Abstract]   [Full Text] [Related]  

  • 85. Tofacitinib for polyarteritis nodosa: a tailored therapy.
    Rimar D; Alpert A; Starosvetsky E; Rosner I; Slobodin G; Rozenbaum M; Kaly L; Boulman N; Awisat A; Ginsberg S; Zilber K; Shen-Orr SS
    Ann Rheum Dis; 2016 Dec; 75(12):2214-2216. PubMed ID: 27558986
    [No Abstract]   [Full Text] [Related]  

  • 86. TOFACITINIB IN THE MANAGEMENT OF ULCERATIVE COLITIS REFRACTORY TO ANTI-TNF AND ANTI-INTEGRIN THERAPIES.
    Teixeira FV; Damião AOMC; Kotze PG
    Arq Gastroenterol; 2018; 55(2):198-200. PubMed ID: 30043874
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Cost-effectiveness of Tofacitinib in the Treatment of Moderate to Severe Rheumatoid Arthritis in South Korea.
    Lee MY; Park SK; Park SY; Byun JH; Lee SM; Ko SK; Lee EK
    Clin Ther; 2015 Aug; 37(8):1662-76.e2. PubMed ID: 26243076
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Tofacitinab in renal transplantation.
    Zand MS
    Transplant Rev (Orlando); 2013 Jul; 27(3):85-9. PubMed ID: 23849222
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors.
    Gladman D; Rigby W; Azevedo VF; Behrens F; Blanco R; Kaszuba A; Kudlacz E; Wang C; Menon S; Hendrikx T; Kanik KS
    N Engl J Med; 2017 Oct; 377(16):1525-1536. PubMed ID: 29045207
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure.
    Liu LY; Strassner JP; Refat MA; Harris JE; King BA
    J Am Acad Dermatol; 2017 Oct; 77(4):675-682.e1. PubMed ID: 28823882
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Application of the Itch Severity Score in patients with moderate-to-severe plaque psoriasis: Clinically important difference and responder analyses.
    Mamolo CM; Bushmakin AG; Cappelleri JC
    J Dermatolog Treat; 2015 Apr; 26(2):121-3. PubMed ID: 24716586
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Nail involvement in patients with moderate-to-severe alopecia areata treated with oral tofacitinib.
    Lee JS; Huh CH; Kwon O; Yoon HS; Cho S; Park HS
    J Dermatolog Treat; 2018 Dec; 29(8):819-822. PubMed ID: 29658800
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Tofacitinib: A Review in Psoriatic Arthritis.
    Paik J; Deeks ED
    Drugs; 2019 Apr; 79(6):655-663. PubMed ID: 30895473
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in Phase III randomised clinical trials of tofacitinib.
    Bird P; Hall S; Nash P; Connell CA; Kwok K; Witcombe D; Thirunavukkarasu K
    RMD Open; 2019; 5(1):e000742. PubMed ID: 30886732
    [TBL] [Abstract][Full Text] [Related]  

  • 95. A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease.
    Sandborn WJ; Ghosh S; Panes J; Vranic I; Wang W; Niezychowski W;
    Clin Gastroenterol Hepatol; 2014 Sep; 12(9):1485-93.e2. PubMed ID: 24480677
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Tofacitinib suppresses disease activity and febrile attacks in a patient with coexisting rheumatoid arthritis and familial Mediterranean fever.
    Gök K; Cengiz G; Erol K; Ozgocmen S
    Acta Reumatol Port; 2017; 42(1):88-90. PubMed ID: 28371574
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment.
    Strober B; Buonanno M; Clark JD; Kawabata T; Tan H; Wolk R; Valdez H; Langley RG; Harness J; Menter A; Papp K
    Br J Dermatol; 2013 Nov; 169(5):992-9. PubMed ID: 23855761
    [TBL] [Abstract][Full Text] [Related]  

  • 98. The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis.
    Boyle DL; Soma K; Hodge J; Kavanaugh A; Mandel D; Mease P; Shurmur R; Singhal AK; Wei N; Rosengren S; Kaplan I; Krishnaswami S; Luo Z; Bradley J; Firestein GS
    Ann Rheum Dis; 2015 Jun; 74(6):1311-6. PubMed ID: 25398374
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Tofacitinib in paediatric dermatoses: a narrative review.
    Agarwal I; Panda M; Das A
    Clin Exp Dermatol; 2022 Jul; 47(7):1256-1264. PubMed ID: 35279865
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Successful treatment of refractory palmoplantar psoriasis in a psoriatic arthritis patient with the JAK inhibitor tofacitinib.
    Valor-Méndez L; Sticherling M; Kleyer A; Schett G
    Clin Exp Rheumatol; 2021; 39(1):228. PubMed ID: 32828149
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.